Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.
Allison VoisinCatherine TerretCamille SchifflerAnne-Sophie BidauxHelene VanackerMarlène Perrin-NiquetMaud BarberyArmelle VinceneuxLauriane EberstPierre StéphanGwenaele GarinDany SpaggiariDavid PérolYenkel Grinberg-BleyerPhilippe Alexandre CassierPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Xevinapant combined with pembrolizumab was well tolerated with no unexpected AEs. However, antitumor activity was low.